Figure 3c shows that the frequencies of lytic-specificCD8+ T cells, CD8+ EM T cells,CD8+ EMRA T cells and CD8+ EM/EMRA T cellsin the PBMC were lower in HLA-A*02+ patients than inHLA-A*02+ healthy subjects, thus confirming the decreasedCD8+ T-cell response to EBV lytic phase antigens in MS. This evidence concerns the gene CD8A and myeloid sarcoma.